Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury

Naohiro Uezono, Yicheng Zhu, Yusuke Fujimoto, Tetsuro Yasui, Taito Matsuda, Masahide Nakajo, Masahiko Abematsu, Takao Setoguchi, Shuji Mori, Hideo K. Takahashi, Setsuro Komiya, Masahiro Nishibori, Kinichi Nakashima

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Together with residual host neurons, transplanted neural stem cell (NSC)-derived neurons play a critical role in reconstructing disrupted neural circuits after spinal cord injury (SCI). Since a large number of tracts are disrupted and the majority of host neurons die around the lesion site as the damage spreads, minimizing this spreading and preserving the lesion site are important for attaining further improvements in reconstruction. High mobility group box-1 (HMGB1) is a damage-associated molecular pattern protein that triggers sterile inflammation after tissue injury. In the ischemic and injured brain, neutralization of HMGB1 with a specific antibody reportedly stabilizes the blood-brain barrier, suppresses inflammatory cytokine expression, and improves functional recovery. Using a SCI model mouse, we here developed a combinatorial treatment for SCI: administering anti-HMGB1 antibody prior to transplantation of NSCs derived from human induced pluripotent stem cells (hiPSC-NSCs) yielded a dramatic improvement in locomotion recovery after SCI. Even anti-HMGB1 antibody treatment alone alleviated blood-spinal cord barrier disruption and edema formation, and increased the number of neurites from spared axons and the survival of host neurons, resulting in functional recovery. However, this recovery was greatly enhanced by the subsequent hiPSC-NSC transplantation, reaching an extent that has never before been reported. We also found that this improved recovery was directly associated with connections established between surviving host neurons and transplant-derived neurons. Taken together, our results highlight combinatorial treatment with anti-HMGB1 antibody and hiPSC-NSC transplantation as a promising novel therapy for SCI. Stem Cells 2018;36:737–750.

Original languageEnglish
Pages (from-to)737-750
Number of pages14
JournalSTEM CELLS
Volume36
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Neural Stem Cells
Stem Cell Transplantation
Spinal Cord Injuries
Induced Pluripotent Stem Cells
Neurons
Antibodies
Therapeutics
Neurites
Locomotion
Blood-Brain Barrier
Axons
Edema
Spinal Cord
Stem Cells
Transplantation
Cytokines
Inflammation
Transplants
Survival
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury. / Uezono, Naohiro; Zhu, Yicheng; Fujimoto, Yusuke; Yasui, Tetsuro; Matsuda, Taito; Nakajo, Masahide; Abematsu, Masahiko; Setoguchi, Takao; Mori, Shuji; Takahashi, Hideo K.; Komiya, Setsuro; Nishibori, Masahiro; Nakashima, Kinichi.

In: STEM CELLS, Vol. 36, No. 5, 01.05.2018, p. 737-750.

Research output: Contribution to journalArticle

Uezono, N, Zhu, Y, Fujimoto, Y, Yasui, T, Matsuda, T, Nakajo, M, Abematsu, M, Setoguchi, T, Mori, S, Takahashi, HK, Komiya, S, Nishibori, M & Nakashima, K 2018, 'Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury', STEM CELLS, vol. 36, no. 5, pp. 737-750. https://doi.org/10.1002/stem.2802
Uezono, Naohiro ; Zhu, Yicheng ; Fujimoto, Yusuke ; Yasui, Tetsuro ; Matsuda, Taito ; Nakajo, Masahide ; Abematsu, Masahiko ; Setoguchi, Takao ; Mori, Shuji ; Takahashi, Hideo K. ; Komiya, Setsuro ; Nishibori, Masahiro ; Nakashima, Kinichi. / Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury. In: STEM CELLS. 2018 ; Vol. 36, No. 5. pp. 737-750.
@article{f12a13b0069348a59eb6cfb4e2c744f8,
title = "Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury",
abstract = "Together with residual host neurons, transplanted neural stem cell (NSC)-derived neurons play a critical role in reconstructing disrupted neural circuits after spinal cord injury (SCI). Since a large number of tracts are disrupted and the majority of host neurons die around the lesion site as the damage spreads, minimizing this spreading and preserving the lesion site are important for attaining further improvements in reconstruction. High mobility group box-1 (HMGB1) is a damage-associated molecular pattern protein that triggers sterile inflammation after tissue injury. In the ischemic and injured brain, neutralization of HMGB1 with a specific antibody reportedly stabilizes the blood-brain barrier, suppresses inflammatory cytokine expression, and improves functional recovery. Using a SCI model mouse, we here developed a combinatorial treatment for SCI: administering anti-HMGB1 antibody prior to transplantation of NSCs derived from human induced pluripotent stem cells (hiPSC-NSCs) yielded a dramatic improvement in locomotion recovery after SCI. Even anti-HMGB1 antibody treatment alone alleviated blood-spinal cord barrier disruption and edema formation, and increased the number of neurites from spared axons and the survival of host neurons, resulting in functional recovery. However, this recovery was greatly enhanced by the subsequent hiPSC-NSC transplantation, reaching an extent that has never before been reported. We also found that this improved recovery was directly associated with connections established between surviving host neurons and transplant-derived neurons. Taken together, our results highlight combinatorial treatment with anti-HMGB1 antibody and hiPSC-NSC transplantation as a promising novel therapy for SCI. Stem Cells 2018;36:737–750.",
author = "Naohiro Uezono and Yicheng Zhu and Yusuke Fujimoto and Tetsuro Yasui and Taito Matsuda and Masahide Nakajo and Masahiko Abematsu and Takao Setoguchi and Shuji Mori and Takahashi, {Hideo K.} and Setsuro Komiya and Masahiro Nishibori and Kinichi Nakashima",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/stem.2802",
language = "English",
volume = "36",
pages = "737--750",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Prior Treatment with Anti-High Mobility Group Box-1 Antibody Boosts Human Neural Stem Cell Transplantation-Mediated Functional Recovery After Spinal Cord Injury

AU - Uezono, Naohiro

AU - Zhu, Yicheng

AU - Fujimoto, Yusuke

AU - Yasui, Tetsuro

AU - Matsuda, Taito

AU - Nakajo, Masahide

AU - Abematsu, Masahiko

AU - Setoguchi, Takao

AU - Mori, Shuji

AU - Takahashi, Hideo K.

AU - Komiya, Setsuro

AU - Nishibori, Masahiro

AU - Nakashima, Kinichi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Together with residual host neurons, transplanted neural stem cell (NSC)-derived neurons play a critical role in reconstructing disrupted neural circuits after spinal cord injury (SCI). Since a large number of tracts are disrupted and the majority of host neurons die around the lesion site as the damage spreads, minimizing this spreading and preserving the lesion site are important for attaining further improvements in reconstruction. High mobility group box-1 (HMGB1) is a damage-associated molecular pattern protein that triggers sterile inflammation after tissue injury. In the ischemic and injured brain, neutralization of HMGB1 with a specific antibody reportedly stabilizes the blood-brain barrier, suppresses inflammatory cytokine expression, and improves functional recovery. Using a SCI model mouse, we here developed a combinatorial treatment for SCI: administering anti-HMGB1 antibody prior to transplantation of NSCs derived from human induced pluripotent stem cells (hiPSC-NSCs) yielded a dramatic improvement in locomotion recovery after SCI. Even anti-HMGB1 antibody treatment alone alleviated blood-spinal cord barrier disruption and edema formation, and increased the number of neurites from spared axons and the survival of host neurons, resulting in functional recovery. However, this recovery was greatly enhanced by the subsequent hiPSC-NSC transplantation, reaching an extent that has never before been reported. We also found that this improved recovery was directly associated with connections established between surviving host neurons and transplant-derived neurons. Taken together, our results highlight combinatorial treatment with anti-HMGB1 antibody and hiPSC-NSC transplantation as a promising novel therapy for SCI. Stem Cells 2018;36:737–750.

AB - Together with residual host neurons, transplanted neural stem cell (NSC)-derived neurons play a critical role in reconstructing disrupted neural circuits after spinal cord injury (SCI). Since a large number of tracts are disrupted and the majority of host neurons die around the lesion site as the damage spreads, minimizing this spreading and preserving the lesion site are important for attaining further improvements in reconstruction. High mobility group box-1 (HMGB1) is a damage-associated molecular pattern protein that triggers sterile inflammation after tissue injury. In the ischemic and injured brain, neutralization of HMGB1 with a specific antibody reportedly stabilizes the blood-brain barrier, suppresses inflammatory cytokine expression, and improves functional recovery. Using a SCI model mouse, we here developed a combinatorial treatment for SCI: administering anti-HMGB1 antibody prior to transplantation of NSCs derived from human induced pluripotent stem cells (hiPSC-NSCs) yielded a dramatic improvement in locomotion recovery after SCI. Even anti-HMGB1 antibody treatment alone alleviated blood-spinal cord barrier disruption and edema formation, and increased the number of neurites from spared axons and the survival of host neurons, resulting in functional recovery. However, this recovery was greatly enhanced by the subsequent hiPSC-NSC transplantation, reaching an extent that has never before been reported. We also found that this improved recovery was directly associated with connections established between surviving host neurons and transplant-derived neurons. Taken together, our results highlight combinatorial treatment with anti-HMGB1 antibody and hiPSC-NSC transplantation as a promising novel therapy for SCI. Stem Cells 2018;36:737–750.

UR - http://www.scopus.com/inward/record.url?scp=85045886957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045886957&partnerID=8YFLogxK

U2 - 10.1002/stem.2802

DO - 10.1002/stem.2802

M3 - Article

C2 - 29517828

AN - SCOPUS:85045886957

VL - 36

SP - 737

EP - 750

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -